Palomo et al found that DNMT3A was always the founder mutation in MDS/MPN‐RS‐T patients who had it, whereas ASXL1 and TET2 never originated prior to SF3B1 [3]. This evidence concerns the gene DNMT3A and myeloproliferative disorder.